28432481|t|The Pretreatment Neutrophil-to-Lymphocyte Ratio is a Prognostic Determinant of T3 - 4 Hypopharyngeal Squamous Cell Carcinoma
28432481|a|This study aimed to investigate the clinicopathological factors that influence recurrence and survival in patients who undergo operations for T3 - 4 hypopharyngeal squamous cell carcinomas (SCCs). One hundred and five patients who underwent surgery between 2001 and 2008 for advanced hypopharyngeal SCCs were consecutively enrolled and reviewed. The pretreatment neutrophil-to-lymphocyte ratio (NLR; median 3.22, range 0.62-46.50) was associated with disease recurrence and patient survival. A difference in the 5-year cumulative disease recurrence rate between patients with high (≥3.22) and low (<3.22) NLRs was significant (60.4 and 36.5%, respectively; p = 0.004). A multivariate analysis confirmed that an NLR ≥3.22 was an independent indicator of a poor prognosis for advanced hypopharyngeal SCC, as per the following parameters: overall survival (hazard ratio [HR] 2.53, 95% confidence interval [CI] 1.48-4.30, p = 0.001), disease-specific survival (HR 2.45, 95% CI 1.38-4.34, p = 0.002), and disease-free survival (HR 2.18, 95% CI 1.24-3.83, p = 0.007). Additional prognostic factors per the survival analyses included lymph node density, surgical margin, lymphovascular invasion, and perineural invasion. An NLR ≥3.22 is associated with a higher risk of disease recurrence and poor survival in patients with T3 - 4 hypopharyngeal SCCs. We propose the use of the NLR to broaden the current TNM staging system; the development of a more effective treatment protocol for patients with high NLRs will be essential.
28432481	4	16	Pretreatment	T052	C3539076
28432481	17	47	Neutrophil-to-Lymphocyte Ratio	T081	C0392762
28432481	53	75	Prognostic Determinant	T201	C1514474
28432481	79	81	T3	T191	C0280390
28432481	84	124	4 Hypopharyngeal Squamous Cell Carcinoma	T191	C0280391
28432481	145	156	investigate	T169	C1292732
28432481	194	203	influence	T077	C4054723
28432481	204	214	recurrence	T046	C2825055
28432481	219	227	survival	T169	C0220921
28432481	231	239	patients	T101	C0030705
28432481	252	262	operations	T061	C0543467
28432481	267	269	T3	T191	C0280390
28432481	272	313	4 hypopharyngeal squamous cell carcinomas	T191	C0280391
28432481	315	319	SCCs	T191	C0280321
28432481	343	351	patients	T101	C0030705
28432481	366	373	surgery	T061	C0543467
28432481	400	408	advanced	T080	C0205179
28432481	409	423	hypopharyngeal	T029	C0020629
28432481	424	428	SCCs	T191	C0280321
28432481	448	456	enrolled	T058	C1254363
28432481	461	469	reviewed	T080	C1709940
28432481	475	487	pretreatment	T052	C3539076
28432481	488	518	neutrophil-to-lymphocyte ratio	T081	C0392762
28432481	520	523	NLR	T081	C0392762
28432481	560	575	associated with	T080	C0332281
28432481	576	594	disease recurrence	T046	C2825055
28432481	599	606	patient	T101	C0030705
28432481	607	615	survival	T169	C0220921
28432481	619	629	difference	T080	C1705242
28432481	644	654	cumulative	T080	C1511559
28432481	655	673	disease recurrence	T046	C2825055
28432481	674	678	rate	T081	C1521828
28432481	687	695	patients	T101	C0030705
28432481	701	705	high	T080	C0205250
28432481	718	721	low	T080	C0205251
28432481	730	734	NLRs	T081	C0392762
28432481	739	750	significant	T078	C0750502
28432481	796	817	multivariate analysis	T081	C0026777
28432481	818	827	confirmed	T033	C0750484
28432481	836	839	NLR	T081	C0392762
28432481	853	864	independent	T033	C1299583
28432481	865	874	indicator	T078	C0392360
28432481	880	894	poor prognosis	T033	C0278252
28432481	899	907	advanced	T080	C0205179
28432481	908	922	hypopharyngeal	T029	C0020629
28432481	923	926	SCC	T191	C0280321
28432481	939	948	following	T079	C0332282
28432481	949	959	parameters	T077	C0549193
28432481	961	977	overall survival	T081	C4086681
28432481	979	991	hazard ratio	T081	C2985465
28432481	993	995	HR	T081	C2985465
28432481	1007	1026	confidence interval	T081	C0009667
28432481	1028	1030	CI	T081	C0009667
28432481	1055	1080	disease-specific survival	T081	C2986538
28432481	1082	1084	HR	T081	C2985465
28432481	1095	1097	CI	T081	C0009667
28432481	1125	1146	disease-free survival	T081	C0242793
28432481	1148	1150	HR	T081	C2985465
28432481	1161	1163	CI	T081	C0009667
28432481	1198	1216	prognostic factors	T201	C1514474
28432481	1225	1242	survival analyses	T062	C0038953
28432481	1252	1270	lymph node density	T081	C0392762
28432481	1272	1287	surgical margin	T023	C0229985
28432481	1289	1312	lymphovascular invasion	T033	C1708790
28432481	1318	1337	perineural invasion	T033	C1317608
28432481	1342	1345	NLR	T081	C0392762
28432481	1355	1370	associated with	T080	C0332281
28432481	1373	1384	higher risk	T033	C3843761
28432481	1388	1406	disease recurrence	T046	C2825055
28432481	1411	1415	poor	T080	C0542537
28432481	1416	1424	survival	T169	C0220921
28432481	1428	1436	patients	T101	C0030705
28432481	1442	1444	T3	T191	C0280390
28432481	1447	1468	4 hypopharyngeal SCCs	T191	C0280391
28432481	1485	1491	use of	T169	C1524063
28432481	1496	1499	NLR	T081	C0392762
28432481	1515	1522	current	T079	C0521116
28432481	1523	1541	TNM staging system	T185	C1515169
28432481	1547	1558	development	T169	C1527148
28432481	1569	1578	effective	T080	C1704419
28432481	1579	1597	treatment protocol	T061	C0040808
28432481	1602	1610	patients	T101	C0030705
28432481	1616	1620	high	T080	C0205250
28432481	1621	1625	NLRs	T081	C0392762
28432481	1634	1643	essential	T080	C0205224